Cerevel Therapeutics Holdings Inc
CERE
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.19B
Close$
$3.15
93% downside
Current Fair Value
93% downsideOvervalued by 93% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.19 Billion |
|---|---|
| Enterprise Value | $8.24 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.67 |
| Beta | 1.41 |
| Outstanding Shares | 181,610,675 |
Return
| Return on Equity | -81.58% |
|---|---|
| Return on Assets | -40.85% |
| Return on Invested Capital | -45.71% |
Valuation & Multiples
| P/E Ratio | -16.83 |
|---|---|
| PEG | -63.54 |
| Price to Sales | - |
| Price to Book Ratio | 14.99 |
| Enterprise Value to Revenue | 998.77 |
| Enterprise Value to EBIT | -17.27 |
| Enterprise Value to Net Income | -18 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.65 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Cerevel Therapeutics Holdings Inc
122 employeesCerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focu...